Eye (CNV DMO PDR RVO) Programs in Pharmaceutical Benefits Scheme (PBS) 012-18032900
This document outlines details of PBS-subsidised aflibercept, brolucizumab, dexamethasone intravitreal implant, faricimab and ranibizumab for patients with eye conditions.
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.
On this page:
Subfoveal choroidal neovascularisation (CNV) quick reference
Diabetic macular oedema (DMO) quick reference
Proliferative diabetic retinopathy (PDR) and/or DMO quick reference
Retinal vein occlusion (RVO) quick reference
Eye program assessing table for CNV
Subfoveal choroidal neovascularisation (CNV) quick reference
Table 1
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
Initial PB072 form |
Written Electronic S85: aflibercept brolucizumab faricimab ranibizumab |
No |
OPA |
Must be treated by an:
|
Yes |
Grandfather PB377 form |
Written Electronic S85: aflibercept 8 mg/0.07 mL |
No |
OPA |
Must be treated by an:
|
Yes |
Continuing |
Streamlined S85: aflibercept faricimab ranibizumab |
No |
N/A |
Must be treated by an:
|
N/A |
Continuing |
Telephone Electronic S85: brolucizumab |
No |
OPA |
Must be treated by an:
|
Yes |
Diabetic macular oedema (DMO) quick reference
Table 2
Proliferative diabetic retinopathy (PDR) and/or DMO quick reference
Table 3
Retinal vein occlusion (RVO) quick reference
Table 4
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
Initial PB154 form |
Written Electronic S85: aflibercept dexamethasone intravitreal implant faricimab ranibizumab |
No |
OPA |
Must be treated by an:
|
Yes |
Continuing |
Streamlined S85: aflibercept dexamethasone intravitreal implant faricimab ranibizumab |
No |
N/A |
Must be treated by an:
|
N/A |
Eye program assessing table for CNV
Table 5